Algorae Pharmaceuticals Limited
1AI
Clasificación en acciones
#30930
Algorae Pharmaceuticals Limited, a company established in 1987 and based in... Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Precio por acción
$0.00705285
Capitalización bursátil
$14.30M
Cambio (1 día)
0.00%
Cambio (1 año)
-30.71%
País
AU
Comercio Algorae Pharmaceuticals Limited (1AI)
Categoría
Healthcare
Capitalización de mercado de Algorae Pharmaceuticals Limited(1AI)
Capitalización bursátil: $14.30M
A fecha de October 2026, Algorae Pharmaceuticals Limited tiene una capitalización de mercado de $14.30M. Esto convierte a Algorae Pharmaceuticals Limited en la 30930th empresa más valiosa del mundo por capitalización bursátil, según nuestros datos. La capitalización bursátil es el valor total de mercado de las acciones en circulación de una empresa que cotiza en bolsa y se utiliza comúnmente para medir su valor.
Historial de capitalización de mercado de Algorae Pharmaceuticals Limited desde 2004 hasta 2026
1AI en comparación con los más populares 5 títulos stocks
